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Anti-microbial peptides (AMPs) were originally thought to exert protecting
actions against bacterial infection by disintegrating bacterial membranes. Upon
identiﬁcation of internal bacterial targets, the view changed and moved toward
inhibition of prokaryote-speciﬁc biochemical processes. However, the level of none
of these activities can explain the robust efﬁcacy of some of these peptides in animal
models of systemic and cutaneous infections. A rapidly growing panel of reports
suggests that AMPs, now called host-defense peptides (HDPs), act through activating
the immune system of the host. This includes recruitment and activation of macro-
phages and mast cells, inducing chemokine production and altering NF-κB signaling
processes. As a result, both pro- and anti-inﬂammatory responses are elevated together
with activation of innate and adaptive immunity mechanisms, wound healing, and
apoptosis. HDPs sterilize the systemic circulation and local injury sites signiﬁcantly
more efﬁciently than pure single-endpoint in vitromicrobiological or biochemical data
would suggest and actively aid recovering from tissue damage after or even without
bacterial infections. However, the multiple and, often opposing, immunomodulatory
functions of HDPs require exceptional care in therapeutic considerations.
Keywords: angiogenesis, anti-inﬂammatory responses, chemokines,
macrophages, wound healing
Introduction
Anti-microbial peptides (AMPs) are among the ﬁrst line defense mechan-
isms of animals [1]. These gene-encoded 10–50 amino acid residue polyamides
are either strategically deployed at barrier sites where bacterial infection can occur
such as the skin and epithelial mucosa in mammals or rapidly delivered to the
injury and infection sites in response of invading microorganisms [2]. The two
major AMP families in humans are defensins and cathelicidins [3], both produced
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by neutrophils and epithelial cells and indeed share similar roles in lung and other
tissue immunity [4]. In support, administration of a human neutrophil-derived
defensin reduces bacterial load in the infected peritoneal cavity 24 h after infection
in an experimental Klebsiella pneumoniae infection in mice [5]. Likewise, when
administrating post-Francisella tularensis infection, the cathelicidin-derived pep-
tide LL-37 protects against respiratory tularemia in a murine model [6]. As
opposed to the mammalian immune system that activates both innate and adaptive
immunities, lower animals such as insects rely almost solely on a panel of AMP
against bacteria in environments where these pathogens strive and are abundant
[7]. Their importance gained widespread recognition in 2011, when Jules Hoff-
mann received the Nobel Prize in physiology or medicine for his pioneering work
on innate immunity mechanisms, including identiﬁcation of AMP from insects
and discovery of the genetic background of their synthesis [8]. Unfortunately
neither native drosocin [9] nor pyrrhocoricin [10] that the Hoffmann group
isolated from insects after pricking them with Escherichia coli shows efﬁcacy
against experimental E. coli infection in higher animals, such as mice [11]. Thus, it
must be something else than direct killing of microbes that make mammalian-
derived peptides active and insect-derived peptides inactive in animal models of
bacterial infections.
Most AMPs are cationic at pH= 7, i.e., their sequence contains positively
charged residues, arginine, lysine, and histidine, in excess of the negatively
charged aspartic and glutamic acids. It appeared quite logical that the ﬁrst
explanation of their mode of action was accumulation on the negatively charged
bacterial membrane surface up to a threshold level leading to membrane perme-
ation/disintegration [12]. Apparently, the ﬁne details of the membrane–peptide
interaction are dependent upon the speciﬁcs of both players of the association, as
while magainin, a frog skin AMP, lies in the plane of the bi-layer; M2 delta, a
helical segment of the nicotinic acetylcholine receptor, spans the membrane,
perpendicular to the bi-layer plane [13]. It slowly became clear that the biophysical
assumptions of neither of the two main membrane-perturbing models (barrel-stave
and Shai–Matsuzaki–Huang carpet) are reliable for reaching structure–function
conclusions [14]. The last push for alternative modes of action came after the
observations that many AMPs fail to modulate membrane permeability at their
microbiologically active concentration [15].
Since the discovery of magainins, AMPs were considered viable drug
candidates and entered many clinical trials. Pexiganan, a synthetic 22-amino acid
version of magainin-2, shows activity in healing of diabetic foot ulcer wounds in
Phase-III trials [16]; omiganan, a bovine peptide origin AMP, was in Phase-II
clinical trials against mild-to-moderate acne [17], and novexatin, a cationic cyclic
heptapeptide, is close to registration as a topical treatment for fungal infections of
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the toenail [18]. The Holy Grail of all drug development platforms is ﬁnding a
novel biopolymer target, speciﬁc for the given disease, in our case for bacterial
survival, virulence or toxicity. In that regard, newly discovered activities of AMP
include inhibition of RNA [19] or protein synthesis [20], attenuation of protein
folding [21] or lipid complexation [22], and activation of microbial autolytic
systems [23] or deactivation of bacterial toxins [24]. While these activities can
explain some positive in vivo results that bacterial membrane disintegration
cannot, they are unable to account for the success of many systemic and local
infection treatments in the absence of in vitro killing of bacteria or inactivating the
newly recognized target proteins.
The complexity of the effects of AMP in infection and inﬂammation
suggests that these biopolymers play a strong role in activating the immune
system of the hosts [25]. Just a single recent review lists many major functions for
AMPs, such as direct anti-microbial effects, clearance of endotoxins, chemotaxis,
modiﬁcation of anti- and pro-inﬂammatory immune responses, wound healing and
tissue repair, angiogenesis, and apoptosis [26]. Historically, lactoferricin analogs
were found ﬁrst to protect mice from infection through both anti-microbial activity
and immunostimulatory effects [27]. The best example of the cooperation between
microbiological and immunological effects came when a hyaluronic acid-binding
peptide, preventing staphylococcal infections, was considered an immunological
therapeutic agent rather than an antibiotic in spite of its sequence demonstrating
striking similarity to cationic AMP [28]. Later research on AMPs was extended to
activation of macrophage activity [29] and upregulation of anti-inﬂammatory
cytokine production [30]. Because the true role of cationic peptides is to enhance
chemotaxis or growth factor activation, it was suggested that these peptides were
misclassiﬁed as anti-microbials [31]. Their newly coined name is host-defense
peptides (HDPs) reﬂecting their complex functions in inﬂammatory responses,
chemoattraction, cellular differentiation, and activation of the innate and adaptive
immune systems [32]. Further activities, including angiogenesis, culminate in
effects as far as adjuvant activities in animal models of both bacterial and viral
infections [33]. This review intends to update the view on HDPs with the most
important strategic results and concepts on the various immunomodulatory
activities from the past few years.
Wide Spectrum of Immune Stimulatory Peptides
Cathelicidins and defensins activate a long series of receptors, signaling
pathways, and transcription factors [34]. Some of the effects of the cathelicidin
family of HDP will be detailed later. β-Defensin 131 enhances the expression of
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cytokines IL-1, IL-6, and IL-12, as well as chemokines CCL20, CCL22, and
CXL8 in human prostate cancer cells upon concomitant lipoteichoic acid treatment
[35]. These activities proceed through the TLR2/NF-κB signaling pathway
promoting strong immune responses in a cellular environment characteristic to
gram-positive bacterial infections. β-Defensins are chemotactic for immature
monocytes and memory T cells [36]. Human β-defensin-3 activates monocytes
through both CD86 and CD80 upregulation signaling suggesting that autocrine
activation of the ionotropic P2X7 receptor plays an important role in shaping the
inﬂammatory microenvironment [37]. β-Defensins activate primary macrophages
along with enhancing pro-inﬂammatory responses to support inﬂammatory
responses initiated by TLR ligands [38].
Apidaecin is a honey bee originated proline–arginine-rich peptide [7]. At
high concentrations, apidaecin upregulates the production of the T-cell co-
stimulatory molecule CD80 as well as cytokines and chemokines in macrophages
but not in monocytes [39]. Low concentrations (5–10 μM) of apidaecin partially
inhibit lipopolysaccharide (LPS)-induced increase in class II MHC, and CD86
and release of IL-6 and in TNF-α in macrophages. Interestingly, at low con-
centrations, the peptide also inhibits IL-6, TNF-α, FGF, and eotaxin in monocytes.
A derivative of apidaecin, Api88, also inhibits LPS-induced TNF-α production in
a concentration-dependent manner in both monocytes and mast cells, although
resting monocytes do not respond to Api88 [40]. Api88 does not induce migration
or affects the phagocytic activity of monocytes. To add to the complexity of the
issue, another insect-derived AMP, the cecropin-derived peptide HB-107, lacks
anti-microbial activity but, when applied to wounds in mice, induces leukocyte
inﬁltration and keratinocyte hyperplasia [41]. In addition, HB-107 stimulates IL-8
secretion from cultured endothelial cells, an effect that may explain the increase in
leukocyte migration.
The frog antibiotic-based cationic peptide Tiger17 is one of the smallest
HDPs containing only 11 amino acid residues [42]. Tiger17 promotes remarkable
levels of wound healing in a mouse full-thickness skin injury model. The peptide
recruits macrophages to the wound site during the inﬂammatory reaction stage,
activates mitogen-activated protein kinase signaling pathways, aids tissue forma-
tion and tissue remodeling through the release of transforming TGF-β1 and IL-6 in
macrophages, and of signiﬁcance to the previous paragraph, promotes migration
and proliferation of both keratinocytes and ﬁbroblasts leading to re-epithelialization
and granulation.
Dairy products and milk contain a large number of bioactive peptides many
of which exhibit extra-nutritional functions. As evidenced by lactoferricin, in
addition to the frequently cited anti-oxidant and anti-hypertension activities, these
peptides do possess immunomodulatory, anti-inﬂammatory, and anti-microbial
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activities [43]. Here, the sequence diversity moves from cationic peptides to
downright negatively changed molecules and peptides with non-natural amino
acid residues. While the main function of casein phosphopeptides is transporting
calcium, they may also enhance its bioaccessibility [44]. Toothpaste made up of
casein phosphopeptides and amorphous calcium can prevent tooth demineraliza-
tion and improve enamel remineralization [45]. The question remains unsolved if
the anti-cariogenic, cytomodulatory, and immunomodulatory effects of these
peptides are related or these are independent, sequence-speciﬁc events. Another
peptide containing post-translationally modiﬁed residues is nisin that has been
approved by the US Food and Drug Administration for clinical use [46]. Nisin is a
lantibiotic produced by Lactococcus lactis and is primarily used as a food
preservative. Originally considered only as an antibiotic, new data document that
nisin activates human polymorphonuclear neutrophils in vitro and additionally
elevates neutrophil intracellular superoxide levels [47]. Nisin induces responses in
both adaptive and innate immunities leading to cell death.
Stimulation of the immune system can be achieved with signiﬁcantly
lower drug doses than anti-microbial chemotherapy. When indolicidin, a
bovine neutrophil-originated HDP containing 13 amino acid residues, was
coupled to carbon nanotubes or gold nanoparticles, the resulting nanostructures
elicited similar levels of stimulation of immune gene expression and protection
from bacterial challenge at a 1000-fold less concentration than the free peptide
[48]. Likewise, the in vivo anti-bacterial effects of the designer Chex-Arg20
proline–arginine-rich peptide are more extensive when embedded in a nanoﬁber
formulation than after intramuscular administration using only one-tenth of the
active pharmaceutical ingredient [49]. The various cutaneous and wound
healing activities are likely linked to the ability of HDP to activate mast cells
and enhance the production of cytokines (GM-CSF, TNF-α) and chemokines
(IL-8-MCPs and MIPs) at inﬂammation and injury sites [50]. Along these lines,
a polyelectrolyte multilayer ﬁlm based on polyarginine and hyaluronic acid has
a remarkable anti-microbial activity in a ﬁlm format against Staphylococcus
aureus and as well as inhibits the production of inﬂammatory cytokines
released by human primary macrophages [51]. The polyarginine–hyaluronic
acid ﬁlm was embedded into a nanoscale silver coating and was further
functionalized by embedding catestatin, a natural HDP. Indeed, this chimera
ﬁlm is efﬁcacious as an anti-microbial coating against yeast and fungi. Self-
assembling peptides can themselves assemble in nanoﬁber structures [52].
QL6, one of these self-assembled nanomaterial peptides, preserves spinal cord
tissue upon injection into rats 24 h after spinal cord injury. The mode of action
of QL6 is suggested to be a signiﬁcant reduction in apoptosis, inﬂammation,
and astrogliosis [53].
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Pro- and Anti-Inﬂammatory Activities
As opposed to β-defensins, human α-defensins increase the expression of
the pro-inﬂammatory cytokines TNF-α and IL-1 in human monocytes [54].
Likewise, intramuscular injection of synthetic human α-defensin into rainbow
trout induces the transcript expression of genes encoding both pro-inﬂammatory
cytokines (IL-1β, TNF-α, and IL-8) and CC chemokines (CK5B, CK6, and
CK7A) [55]. CD14(–)/CD24(+) cell secreted α-defensins HNP1 (Table I) and
HNP3 suppress the differentiation capabilities of monocytes [56]. This is likely a
sequence-speciﬁc effect, as treatment of immortalized macrophages with a non-
cationic AMP, epinecidin-1 from ﬁsh, fails to induce TNF-α production. Rather,
epinecidin-1 inoculation into mice elevates the plasma level of the anti-
inﬂammatory cytokine IL-10 [57]. Having said this, a C-terminal 15-residue
fragment of human β-defensin exhibits anti-inﬂammatory activity in LPS-treated
mouse macrophages [58]. Signiﬁcantly, the hBD3-3 peptide downregulates
NF-κB-dependent inﬂammation and, in a lung inﬂammation model, reduces
interstitial inﬁltration of polymorphonuclear leukocytes. Os and Os-C are peptides
derived also from the carboxy-terminal region, this time of a tick defensin [59].
Both peptides bind E. coli LPS and inhibit LPS/IFN-γ-induced NO and TNF
production in murine macrophages identical to those used in the previous
paragraph. In addition, they exhibit anti-endotoxin activities and protect macro-
phages from oxidative damage. Neutralization of LPS appears to be a cornerstone
of the anti-inﬂammatory actions of HDP [60]. Production of inﬂammatory
cytokines is inhibited by cationic peptides via neutralizing circulating LPS. These
activities come on top of the promotion of immune cell proliferation, angiogenesis,
and epithelialization.
Synthetic granulysin-derived peptides kill Propionibacterium acnes in
human microcomedone preparations and show anti-inﬂammatory effects [61].
They suppress P. acnes-stimulated cytokine release that suggests their utility as
topical therapeutic agents and competitors of current acne therapies. In other
peritoneal macrophage and peripheral blood mononuclear cells (PBMC) models,
HDPs induce both pro-inﬂammatory and anti-inﬂammatory cytokines indicating
that clinical applications as anti-inﬂammatory, immunosuppressive, and immu-
nostimulatory agents are possible [62]. Talactoferrin-α is a recombinant form of
human lactoferrin, which has been shown to have a wide range of effects on the
immune system [63]. In mice, talactoferrin enhances the production of key repair
inﬂammatory mediators IL-8, IL-6, macrophage inﬂammatory protein-1α, and
TNF-α [64]. Although talactoferrin failed in sepsis therapy, due to its ability
to control, inﬂammation is currently being investigated in cancer studies [65].
A 20-residue N-terminal fragment of porcine lactoferrin prevents LPS-induced
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inﬁltration of macrophages and leukocytes and reduces inﬂammation markers a
well as IL-6, TNF-α, and IFN-γ levels in a porcine epithelial cell line [66]. By
altering the NF-κB signaling pathway, the peptide downregulates the inﬂammatory
response and tight junction structure impairment that occurs after exposure to LPS.
AMP can also induce chemokines and anti- or pro-inﬂammatory cytokines
in the oral mucosa and such should be considered in the early events of oral
inﬂammation [67]. The major allergen of house dust mite can induce pro-
inﬂammatory cytokine production contributing to airway inﬂammation and
allergic asthma [68]. A short, weakly cationic cell penetrating peptide derived
from human eosinophil cationic proteins signiﬁcantly upregulates the production
of pro-inﬂammatory cytokines IL-1β, IL-6, and IL-8 in stimulated PBMC obtained
from house dust mite allergic patients [69]. The upregulation of caspase-1 upon
inﬂammasome activation in monocytes can explain why allergens induce chronic
airway inﬂammation that can lead to allergic asthma. Apparently, the immuno-
modulatory effect of the peptide proceeds through upregulation of IFN-α produc-
tion and not through induction of autophagy and has the potential to be developed
as a new anti-inﬂammatory agent for asthma therapy.
The amino acid sequence of a family of designer AMP is reduced to nothing
else than alternating lysine and leucine residues, sometimes interspersed with
tryptophans or glutamines [70]. These meant to assume amphipathic helical
conformation in membrane-mimetic solvents, although when in contact with
ligands, the truthfulness of this paradigm in real-life membranes is increasingly
debated [71]. WALK11.3, one of these model peptides, inhibits the expression of
inﬂammatory mediators, including NO, COX-2, TNF-α, INF-β, IL-1β, and IL-6 in
LPS-stimulated mouse macrophages [72]. The presence of the peptide attenuates
TLR4-mediated pro-inﬂammatory signals in the TRIF-dependent pathway, while
no effect on downstream signaling in the MyD88-dependent pathway is observed.
Remarkably, WALK11.3 speciﬁcally inhibits TLR4 endocytosis that is essential
for triggering TRIF-mediated signaling in macrophages. When another lysine–
leucine peptide, LLKKK18, is released from dextrin conjugates, it accelerates
wound healing in rats, due to reduced oxidative stress and inﬂammation as
presented by low neutrophil and macrophage inﬁltration and pro-inﬂammatory
cytokine levels [73]. LLKKK18 induces rapid resolution of the inﬂammatory stage
through early M2 macrophage recruitment and stimulates angiogenesis. Yet
another HDP that exhibits potent anti-inﬂammatory activity by inhibiting LPS-
induced NO and pro-inﬂammatory cytokine including TNF-α, IL-6, and IL-1β
production is a cathelicidin from the sea snake Hydrophis cyanocinctus [74]. The
mode of action is reported to be competitive binding to the Toll-TLR4/MD2
complex, preventing LPS attachment and subsequent activation of LPS-induced
inﬂammatory response pathways.
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Speciﬁc Peptide Families
Human cathelicidins
Like many HDPs, the human cathelicidin LL-37 (Table I) kills bacteria
only in low-ionic strength solvents, and becomes inactive when tested in tissue
culture media [75]. Actually, it is in the more physiological conditions when
LL-37 exhibits a wide range of immunomodulatory properties in vitro and these
activities can be recapitulated in animal models [76]. A 24-amino acid-shortened
derivative of the 37-mer LL-37 shows LPS and lipoteichoic acid neutralization
activities similar to the mother peptide but induces lower levels of pro-inﬂam-
matory effects [77]. LL-37 was widely studied and showed to have multiple
immunomodulatory activities, including activation of macrophages, upregula-
tion chemokines and chemokine receptor production, and promotion of wound
healing [76]. Yet another shortened version (19 amino acid residues) of
LL-37 reduces cellular inﬁltration in joints, prevents cartilage degradation, and
suppresses pro-inﬂammatory cytokines in arthritic mice suggesting efﬁcacy
in autoimmune and inﬂammatory diseases [78]. Interestingly, the bovine
cathelicidin-derived peptide IDR-1018 fails to exhibit similar beneﬁcial effects
in the same murine model.
Peptide LL-37 enhances phagocytosis of non-opsonized E. coli by human
macrophages [79]. LL-37 consistently elevates expression of FcγRs on macro-
phages but not the complement receptors CD11b and CD11c. In addition, the
expression of TLR4 and CD14 is increased on LL-37-treated macrophages. Daily
treatment of an inbred laboratory rat strain that spontaneously develops autoim-
mune type-1 diabetes with LL-37 results in enhanced β-cell neogenesis and
upregulation of beneﬁcial gut microbes [80]. In general, by inducing migration
of neutrophils, monocytes and macrophages, eosinophils, and mast cells as well as
prolonging the lifespan of neutrophils, cathelicidins directly modulate epithelial
cell and keratinocyte responses to infecting pathogens [81]. Moreover, they
indirectly balance TLR-mediated responses of monocytes, macrophages, dendritic
cells, epithelial cells, and keratinocytes.
Exogenous LL-37 decreases TNF-α and IL-17 while inducing anti-
inﬂammatory IL-10 and TGF-β production in a monocyte-derived macrophage
cell line infected with Mycobacterium tuberculosis [82]. However, the decreased
production of anti-inﬂammatory cytokines does not reduce anti-mycobacterial
activity supporting the concept that LL-37 modulation of cytokines is independent
of the P2X7 receptor. In a grand scheme, LL-37 controls the expression of both
pro- and anti-inﬂammatory cytokines during infection. In the presence of physio-
logical concentrations of cyanate, LL-37 undergoes compositional changes
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yielding a variety of carbamylated peptides [83]. As small structural changes as
carbamylation have diverse effects on the biological properties of LL-37, most
notably conversion from anti-inﬂammatory to pro-inﬂammatory properties. The
capacity of a chicken-derived cathelicidin analog to modulate chemokine produc-
tion and attenuate endotoxin-induced pro-inﬂammatory responses in immune cells
suggests that cathelicidin-based peptides can serve as leads for the design of
immunomodulatory anti-infectives [84].
Due to the extensive range, and frequently opposing immunomodulatory
activities, a wide spectrum of diseases is suggested to be treated with cathelicidins
and other HDPs, or the opposite, these peptides can serve as targets for therapeutic
interventions. Most reports recommend the utilization of HDP for wound healing
therapy because of the peptides’ ability to harness the mast cell defense of the
hosts, as well as to activate a G-protein-coupled receptor MrgX2 without being
inhibited by LPS [85]. However, the modulation of keratinocyte pro-inﬂammatory
responses by LL-37 suggests novel roles for this peptide in skin inﬂammation
including promotion of IL-17/IL-22/IL-6-associated psoriasis and suppression of
TSLP-associated atopic dermatitis [86]. On one hand, inhibition of LPS-induced
cytokine and adhesion molecule expression in human corneal ﬁbroblasts suggests
that LL-37 can promote the resolution of corneal inﬂammation associated with
bacterial infection [87]. On the other, treatment of various brain cells with LL-37
induces secretion of inﬂammatory cytokines IL-1β and IL-6, chemokines IL-8 and
CCL2, and other materials toxic to human neuroblastoma SH-SY5Y cells [88].
The mode of action involves activation of intracellular pro-inﬂammatory pathways
involving phospho-P38 MAP kinase and phospho-NF-κB proteins, leading to the
conclusion that LL-37 may play a role in chronic neuroinﬂammation that can
be observed in neurodegenerative diseases including Alzheimer’s disease and
Parkinson’s disease.
Innate defense regulators
A family of 12–13 residue peptides, vaguely resembling the C-terminal
half of LL-37 variants in sequence, are named innate defense regulators (IDRs)
[33]. Two of these peptides, IDR-1 and IDR-1002 do not induce pro-inﬂamma-
tory cytokines in human PBMC; rather they suppress pro-inﬂammatory
responses in animal models. IDR-1002 enhances monocyte chemotaxis toward
chemokines CCL3 and CCL5 [89], a phenomenon that correlates with selective
upregulation of CCR5 surface expression. In human ﬁbroblast-like synovio-
cytes, IDR-1002 suppresses the production of MMP-3 induced by IL-1β and
monocyte chemotactic protein-1 [90]. The change in IL-1β-induced proteome is
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evident from the alteration of the expression of NF-κB and JNK pathway
members.
Two other analogs, IDR-HH2 and IDR-1018, fail to kill M. tuberculosis in
vitro to any noticeable degree but reduce bacterium loads in drug-sensitive as well
as drug-resistant M. tuberculosis infections [91]. In a mouse model, the leading
drug candidate, IDR-1018 (Table I) also reduces lung inﬂammation as detected by
reduced pneumonia. In human neutrophils, IDR peptides increase the release of
the neutrophil-generated HDPs (anti-microbial), human α-defensins, and LL-37,
and accelerate neutrophil-mediated killing of E. coli [92]. As a clue for the mode of
action, these HDPs increase the expression of chemokines MCP-1, MP-3, and
GRO-α, all implicated in anti-infective functions leading to immune cell recruit-
ment and anti-infective actions [93]. Consistent with their ability to control
inﬂammation, IDR peptides suppress LPS-mediated neutrophil degranulation,
the release of ROS, and the production of pro-inﬂammatory cytokines, TNF-α
and IL-10 [92].
Anti-lipopolysaccharide peptide
The synthetic AMP Pep19-2.5 (Table I) belongs to the class of synthetic
anti-LPS peptide family. Treatment of murine cardiomyocytes stimulated with
pathogen-associated or host danger-associated molecular patterns with peptide
Pep19-2.5 decreases the inﬂammatory response [94]. The peptide also blocks a
pro-inﬂammatory response induced by soluble heparan sulfate in serum from
patients with gram-negative or gram-positive septic shock. Peptide Pep19-2.5
also interacts with heparanase, an enzyme that is elevated in mammalian sepsis
and consecutively decreases the levels of circulating heparan sulfate fragments
in systemic inﬂammation [95]. Due to these activities, peptide Pep19-2.5 was
suggested to have a potential for pharmaceutical development as a broad-
spectrum anti-inﬂammatory agent in sepsis-induced myocardial inﬂammation
and dysfunction. Moreover, ibuprofen potentiates the anti-inﬂammatory activity
of Pep19-2.5 both in vivo and in vitro, indicating that commonly used non-
steroidal anti-inﬂammatory drugs might be useful to supplement future anti-
sepsis therapies [96].
Designer proline–arginine-rich antibiotics
The peptide dimer A3-APO (Table I) and its monomeric in vivo metabolite
are among the most active HDP in a wide spectrum of bacterial infection models
in mice [97]. Although the APO peptides have only weak activity against
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Acinetobacter baumannii in vitro, when administered either intravenously or
intramuscularly to mice infected with a carbapenem-resistant A. baumannii strain,
the peptides signiﬁcantly reduce bacterial load and increase survival compared
with mice treated with higher doses of imipenem [98]. While the dimer practically
does not kill S. aureus or Proteus mirabilis strains in vitro, when administered
intramuscularly or as an aerosol, it improves mouse survival and reduces bacterial
counts at the infection site and in blood in wound infection or pneumonia models
[99]. The wounds of treated animals lack pus or signs of inﬂammation while in
human PBMC, A3-APO upregulates the expression of the anti-inﬂammatory
cytokines IL-4 and IL-10 by 4–6-fold. One of the modes of actions of APO
peptides might be the prevention of inﬂammation around bacterial inﬁltration. The
efﬁcacies of the A3-APO dimer and its monomeric metabolite were compared in
mouse models of P. acnes intradermal ear infections following administration as
intramuscular or topical treatments [100]. Once again, despite being inactive
against the strain in vitro, in vivo the skin conditions of the experimental animals
were dramatically improved upon peptide treatment regardless of administration
mode or drug valency. APO peptides statistically signiﬁcantly reduce ear thickness
(a measure of inﬂammation) and ear bacterial counts when therapy success is
correlated with the amount of ear connective tissue and level of epithelial
macrophages.
HDPs excel in wound healing models even without bacterial infections and
among the listed underlying immunological changes are macrophage recruit-
ment, leukocyte inﬁltration, chemotaxis, vascularization, and re-epithelialization
as well as reduced, or as opposite, elevated inﬂammation markers [101].
A3-APO improves full-thickness skin abrasion conditions probably due to
macrophage activation [102]. In addition, A3-APO restricts the proliferation
of Bacillus anthracis in infected macrophages by 40–45% compared to untreated
cells both intra- and extracellularly [24]. The APO monomer retains its ability to
close wounds when the peptide is applied to wounds in a polyvinyl alcohol
nanoﬁber dressing [49]. APO-induced re-epithelialization of wounds looks very
similar to those upon treatment with two peptides discussed earlier, the immune
defense regulator IDR-1018 [103] or HB-107, a non-bacteriostatic fragment of
cecropin B [41].
Conclusions
In addition to killing bacteria, HDPs invoke a long range of immune
reactions in the host including macrophage and mast cell recruitment and acti-
vation, cytokine and chemokine release with ensuing signal transduction events,
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and anti- and pro-inﬂammatory signaling. They also upregulate angiogenesis
and downregulate toxin production. All these activities likely work indepen-
dently; efﬁcient AMPs are not necessarily active as anti-endotoxin therapies and
vice versa [104]. In turn, the pleiotropic functions require a drug development
design process that is more complex than that with drugs having only single
functions (and minor side effects). To initiate human trials, small molecule
antibiotics have to clear certain threshold in minimal inhibitory concentrations
and exhibit better efﬁcacy in animal models than existing therapy measures.
Likewise, immunological agents have their own criteria set for moving ahead in
the discovery process. For HDPs, drug developers have to identify a single in
vitro function that explains the superior in vivo efﬁcacy data and present the new
molecular entity to regulatory agencies reﬂecting that function which unlikely
will be bacterial killing. As a consequence, HDPs with similar sequences may
end up in drug classiﬁcation fairly distant from each other. The peptide research
community faces an uphill battle educating regulators, investors, and the
pharmaceutical industry about the advantages and speciﬁcs of these drug
candidates and why and how we can manage the long and cruel clinical trial
process [105].
As HDPs exert a variety of effects resembling cytokines and growth factors
in maintaining normal immune homeostasis, unfortunately, they can also induce
autoimmune diseases [106]. For example, pexiganan induces cross resistance to
human defensin-1, a key component of the innate immune response to infection in
S. aureus [107]. Preventing the ability of the innate immune system to act upon
HDP therapies presents a serious potential risk of the use of cationic peptides in a
clinical setting.
HDPs usually initiate anti-inﬂammatory responses, but sometimes pro-
inﬂammatory signaling is observed. When one of the two activities is detected
in any given assay, it likely depends upon the ﬁne-tuned environment of the actual
measures. The switch between receptor agonist and antagonist activities is a well-
known phenomenon in peptide pharmacology [108] and can occur in minor
sequence-speciﬁc changes and assay design [109]. Based on all available reports,
while for activating the innate immune system and preventing deleterious effects
on infections, both activities should be positively viewed, it is unlikely that HDP
will end up in the treatment arsenal against rheumatoid arthritis or other inﬂam-
matory diseases, as single experiments would suggest. In fact, similar observations
were made on human β-defensins, as the basic cellular functions associated with
these HDPs demonstrate dual impact on health that might be advantageous under
certain conditions and detrimental in others [110]. No doubt HDP will end up on
pharmacy shelves [111]. The question is just when, against what conditions, and
for what price.
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